Altered miRNA Expression as Diagnostics and Therapeutics for Adrenocortical Carcinomas
Posted Apr 13 2011 8:00pm
Description of Invention: This technology describes that altered human miRNA expression such as miRNA-483 and miRNA 100 can accurately predict if a patient's adrenal cortex tumor is benign or malignant. Adrenocortical carcinomas (ACC) are rare but aggressive cancers and typically have a poor prognosis. Currently, there are limited options for molecular diagnosis to distinguish malignant tumors from benign tumors of this type. As a result there are few treatment strategies for ACC.
Additionally, preliminary results suggest that altering the expression of this miRNA in ACC cells can effect cancer cell growth. Therefore, inhibiting a miRNA may serve as a therapeutic option for ACC.
Applications:
Technology can be developed into a diagnostic and prognostic marker for ACC.
Inhibiting miRNA can serve as a potential therapeutics for ACC.
Advantages:
Distinguishes malignant Adrenal cortex tumor from a benign tumor, options for such distinction are limited at this time.
Technology can help in increased and improved diagnosis and therapeutic options for ACC.
Development Status:
Pre-clinical.
Clinical study to test the markers in biopsy and serum samples being planned.
Collaborative Research Opportunity: The Center for Cancer Research, Surgery Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of diagnostic miRNAs and to target these miRNAs for treatment. Please contact John Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information. Click here to view the NCI collaborative opportunity announcement.
Portfolios: Cancer Cancer - Diagnostics Cancer - Therapeutics
For Licensing Information Please Contact: Sabarni Chatterjee Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: chatterjeesa@mail.nih.gov Phone: 301-435-5587 Fax: 301-402-0220
Description of Invention:
This technology describes that altered human miRNA expression such as miRNA-483 and miRNA 100 can accurately predict if a patient's adrenal cortex tumor is benign or malignant. Adrenocortical carcinomas (ACC) are rare but aggressive cancers and typically have a poor prognosis. Currently, there are limited options for molecular diagnosis to distinguish malignant tumors from benign tumors of this type. As a result there are few treatment strategies for ACC.
Additionally, preliminary results suggest that altering the expression of this miRNA in ACC cells can effect cancer cell growth. Therefore, inhibiting a miRNA may serve as a therapeutic option for ACC.
Applications:
Advantages:
Development Status:
Inventors:
Electron Kebebew (NCI)
Erin E Patterson (NCI)
Patent Status:
HHS, Reference No. E-026-2011/0
US, Application No. 12/961,298 filed 06 Dec 2010
Relevant Publication:
Licensing Status:
Available for licensing.
Collaborative Research Opportunity:
The Center for Cancer Research, Surgery Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of diagnostic miRNAs and to target these miRNAs for treatment. Please contact John Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information. Click here to view the NCI collaborative opportunity announcement.
Portfolios:
Cancer
Cancer - Diagnostics
Cancer - Therapeutics
For Licensing Information Please Contact:
Sabarni Chatterjee Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: chatterjeesa@mail.nih.gov
Phone: 301-435-5587
Fax: 301-402-0220
Ref No: 2248
Updated: 04/2011